IMNM

Immunome, Inc. (IMNM) | Rumor.io

Immunome

IMNM

Attention (50-day avg)0%

Attention rank (50-day avg)#1,511

Bullish sentiment (50-day avg)100%

Price to earnings ratio-8.93

Market capitalization2.5B

Earnings per share-2.53

Dividend yield (TTM)—

Revenue (annual)6.9M

Net income (annual)-212.4M

Social

What share of all stock conversation is about IMNM?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Attention	0% -0.01	0% +0	0% 0	0% 0

Aug 10

IMNM's recent strength is attributed to FDA acceptance, which has changed the setup and is now being watched for execution and commercialization.
The current market value of IMNM is $25.03, with a decline of 3.06%.
Many IMNM holders are feeling the pain of the current dip, with some expressing solidarity and seeking comrades in this downturn.

Generated by AI

Sentiment

Of the messages about IMNM that take a side, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Bullish	—	100% 0	100% 0	92.79% +6.53
Bearish	—	0% 0	0% 0	7.21% -6.53

Bullish· Dec 19

Immunome, Inc. ($IMNM) has reached year highs of $28, indicating a strong performance.
The company's CEO has demonstrated confidence in the stock by investing $1 million of his own money at $21.50.
The global desmoid tumor market is expected to reach $5.2 billion by 2033, presenting a significant growth opportunity for $IMNM.

Bearish· Jul 21

$IMNM has a history of being a "pump and dump" stock, with the current price being a bear trap.
The company's recent performance has been weak, with the stock being unable to hold above $17 and experiencing significant declines.
The technical setup for $IMNM is bearish, with indicators such as the Gilligan's Island Sell Setup and Slingshot Bearish suggesting a downward trend.

Generated by AI

Topics

Of the messages about IMNM that carry a topic, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y
Announcements	—	0%	2.74%	65.84%
Technical Analysis	—	4.55%	68.49%	20.9%
Analysts	—	95.45%	28.77%	13.26%
Controversies	—	0%	0%	0%
Earnings	—	0%	0%	0%
Macro	—	0%	0%	0%

Dec 15

Immunome, Inc. (IMNM) announced positive topline results from the Phase 3 RINGSIDE trial of varegacestat in patients with desmoid tumors, meeting the primary endpoint of improved progression-free survival.
The registrational study achieved all key secondary endpoints, including an 84% reduction in the risk of disease progression or death and a 56% objective response rate, the highest reported in a randomized clinical trial for this patient population.
Immunome plans to submit a New Drug Application to the FDA in the second quarter of 2026 and present additional data at an upcoming medical conference.

Generated by AI

Community

Of the messages about IMNM, what share comes from each group?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Regulars	—	98.8%	98.96%	54.53%
Newcomers	—	1.2%	1.04%	45.47%

Regulars· Dec 15

The Phase 3 RINGSIDE trial of varegacestat in patients with desmoid tumors met its primary endpoint, with varegacestat significantly improving progression-free survival compared to placebo.
Immunome's management, led by Clay Siegall, has a strong track record of developing successful drugs, and the company is preparing for a potential commercial launch of varegacestat.
Analysts, including Evercore and Leerink, have raised their price targets on Immunome's stock to $40, citing the positive topline results from the Phase 3 trial and the company's potential for future success.

Newcomers· Aug 10

Newcomers to IMNM are focused on the recent price drop, with losses ranging from 3% to over 3% at $25.03.
The market's reaction to FDA acceptance has changed the setup for IMNM, and now newcomers are watching execution and commercialization.
New investors in IMNM are seeking solidarity with others holding the asset, indicating a desire for community support during this dip.

Generated by AI

BOTHELL, Wash., September 02, 2026--Immunome, Inc. (Nasdaq: IMNM), a clinical-stage targeted oncology company focused on developing first-in-class and best-in-class targeted cancer therapies, today announced that Immunome management will present at H.C. Wainwright’s 28th Annual Global Investment Conference on September 14, 2026, at 11:00 a.m. ET.

28d agoYahoo Finance

Immunome director Isaac Barchas sells $940,453 in common stock

1mo agoInvesting.com

Immunome: Maintaining My 'Strong Buy' Rating With 2 Catalysts On The Horizon (IMNM)

Immunome FDA accepts varegacestat NDA with April 2027 PDUFA, plus ROR1 ADC catalyst and $520M cash. Click here to read more about IMNM.

1mo agoSeeking Alpha

Analysts Offer Insights on Healthcare Companies: Fennec Pharmaceuticals (FENC) and Immunome (IMNM)

Detailed price information for Fennec Pharmaceuticals Inc (FENC-Q) from The Globe and Mail including charting and trades.

1mo agoThe Globe and Mail

Piper Sandler Keeps Their Buy Rating on Immunome (IMNM)

Detailed price information for Immunome Inc (IMNM-Q) from The Globe and Mail including charting and trades.

1mo agoThe Globe and Mail

Also Discussed

Investors talking about IMNM also mention

#	Name	Attention
1	Cue Biopharma, Inc.CUE	0%new
2	Revolution Medicines, Inc.RVMD	0.01%-0.01
3	Edgewise Therapeutics Inc.EWTX	0%new
4	Pharvaris N.V. Ordinary SharesPHVS	0%0
5	Greenland Technologies Holding Corp. Class AGTEC	0%new
6	Themes US Cash Flow Champions ETFLGCF	0%new
7	QuickLogic CorporationQUIK	0%0
8	Texas Capital Bancshares, Inc. 5.75% Fixed Rate Non-Cumulative Perpetual Preferred Stock, Series BTCBIO	0%new
9	Direxion Daily NFLX Bear 1X ETFNFXS	0%0
10	Global X E-Commerce ETFEBIZ	0%0

Immunome, Inc.

Healthcare
Biotechnology

Immunome, Inc. is a clinical-stage biotechnology company focused on developing targeted cancer therapies. The company’s work centers on antibody-drug conjugates and other oncology-focused modalities designed to identify and attack specific disease targets while limiting effects on healthy tissue. Its current portfolio includes late-stage and early-stage programs such as varegacestat for desmoid tumors, IM-1021, and additional investigational assets in radiotherapy and solid-tumor antibody-drug conjugates. Immunome also uses proprietary antibody discovery capabilities to support the identification of novel therapeutic candidates and targets. Based in Bothell, Washington, Immunome operates as a research-driven drug development company serving the oncology market through a pipeline of clinical and preclinical assets.

Website

Location

18702 North Creek Parkway

Bothell, WA, 98011

United States

Social

What share of all stock conversation is about IMNM?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Attention	0% -0.01	0% +0	0% 0	0% 0

Aug 10

IMNM's recent strength is attributed to FDA acceptance, which has changed the setup and is now being watched for execution and commercialization.
The current market value of IMNM is $25.03, with a decline of 3.06%.
Many IMNM holders are feeling the pain of the current dip, with some expressing solidarity and seeking comrades in this downturn.

Generated by AI

Sentiment

Of the messages about IMNM that take a side, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Bullish	—	100% 0	100% 0	92.79% +6.53
Bearish	—	0% 0	0% 0	7.21% -6.53

Bullish· Dec 19

Immunome, Inc. ($IMNM) has reached year highs of $28, indicating a strong performance.
The company's CEO has demonstrated confidence in the stock by investing $1 million of his own money at $21.50.
The global desmoid tumor market is expected to reach $5.2 billion by 2033, presenting a significant growth opportunity for $IMNM.

Bearish· Jul 21

$IMNM has a history of being a "pump and dump" stock, with the current price being a bear trap.
The company's recent performance has been weak, with the stock being unable to hold above $17 and experiencing significant declines.
The technical setup for $IMNM is bearish, with indicators such as the Gilligan's Island Sell Setup and Slingshot Bearish suggesting a downward trend.

Generated by AI

Topics

Of the messages about IMNM that carry a topic, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y
Announcements	—	0%	2.74%	65.84%
Technical Analysis	—	4.55%	68.49%	20.9%
Analysts	—	95.45%	28.77%	13.26%
Controversies	—	0%	0%	0%
Earnings	—	0%	0%	0%
Macro	—	0%	0%	0%

Dec 15

Immunome, Inc. (IMNM) announced positive topline results from the Phase 3 RINGSIDE trial of varegacestat in patients with desmoid tumors, meeting the primary endpoint of improved progression-free survival.
The registrational study achieved all key secondary endpoints, including an 84% reduction in the risk of disease progression or death and a 56% objective response rate, the highest reported in a randomized clinical trial for this patient population.
Immunome plans to submit a New Drug Application to the FDA in the second quarter of 2026 and present additional data at an upcoming medical conference.

Generated by AI

Community

Of the messages about IMNM, what share comes from each group?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Regulars	—	98.8%	98.96%	54.53%
Newcomers	—	1.2%	1.04%	45.47%

Regulars· Dec 15

The Phase 3 RINGSIDE trial of varegacestat in patients with desmoid tumors met its primary endpoint, with varegacestat significantly improving progression-free survival compared to placebo.
Immunome's management, led by Clay Siegall, has a strong track record of developing successful drugs, and the company is preparing for a potential commercial launch of varegacestat.
Analysts, including Evercore and Leerink, have raised their price targets on Immunome's stock to $40, citing the positive topline results from the Phase 3 trial and the company's potential for future success.

Newcomers· Aug 10

Newcomers to IMNM are focused on the recent price drop, with losses ranging from 3% to over 3% at $25.03.
The market's reaction to FDA acceptance has changed the setup for IMNM, and now newcomers are watching execution and commercialization.
New investors in IMNM are seeking solidarity with others holding the asset, indicating a desire for community support during this dip.

Generated by AI

Immunome

Social

Aug 10

Sentiment

Bullish· Dec 19

Bearish· Jul 21

Topics

Dec 15

Community

Regulars· Dec 15

Newcomers· Aug 10

News

Immunome at H.C. Wainwright conference: pipeline bets on ADCs

Immunome to Present at the H.C. Wainwright 28th Annual Global Investment Conference

Immunome director Isaac Barchas sells $940,453 in common stock

Immunome: Maintaining My 'Strong Buy' Rating With 2 Catalysts On The Horizon (IMNM)

Analysts Offer Insights on Healthcare Companies: Fennec Pharmaceuticals (FENC) and Immunome (IMNM)

Piper Sandler Keeps Their Buy Rating on Immunome (IMNM)

Also Discussed

Immunome, Inc.

Company Information

Location

News

Immunome at H.C. Wainwright conference: pipeline bets on ADCs

Immunome to Present at the H.C. Wainwright 28th Annual Global Investment Conference

Immunome director Isaac Barchas sells $940,453 in common stock

Immunome: Maintaining My 'Strong Buy' Rating With 2 Catalysts On The Horizon (IMNM)

Analysts Offer Insights on Healthcare Companies: Fennec Pharmaceuticals (FENC) and Immunome (IMNM)

Piper Sandler Keeps Their Buy Rating on Immunome (IMNM)

Also Discussed

Social

Aug 10

Sentiment

Bullish· Dec 19

Bearish· Jul 21

Topics

Dec 15

Community

Regulars· Dec 15

Newcomers· Aug 10